Argatroban for anticoagulation in continuous renal replacement therapy

Critical Care Medicine

Volumn 37, Issue 6, 2009, Pages 2139-

  Keegan, Shaun P ^a   Ernst, Neil E ^a   Mueller, Eric W ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; ANTICOAGULANT AGENT; PIPECOLIC ACID DERIVATIVE;

ANTICOAGULATION; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; HUMAN; INTENSIVE CARE; KIDNEY FAILURE; LETTER; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; CONTINUOUS RENAL REPLACEMENT THERAPY; MULTIPLE ORGAN FAILURE; THROMBOCYTOPENIA; ACUTE KIDNEY FAILURE; NOTE;

ANTICOAGULANTS; HUMANS; KIDNEY FAILURE, ACUTE; PIPECOLIC ACIDS; RENAL REPLACEMENT THERAPY;

EID: 66449133058     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a60793     Document Type: Letter

References (4)

1. Link A, Girndt M, Selejan S, et al: Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 2009; 37: 105-110
2. Selleng K, Warkentin TE, Greinacher A: Hep-arin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35: 1165-1176
3. Keegan SP, Gallagher EM, Ernst NE, et al: Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed hep-arin-induced thrombocytopenia. Ann Pharmacother 2009; 43:19-27
4. Beiderlinden M, Treschan TA, Gorlinger K, et al: Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007; 41:749-754